Association of fluconazole pharmacodynamics with mortality in patients with candidemia

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3022-3028

  Baddley, John W ^a,c   Patel, Mukesh ^a,c   Bhavnani, Sujata M ^d   Moser, Stephen A ^b   Andes, David R ^e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d ORDWAY RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CONTROLLED STUDY; FEMALE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIVARIATE ANALYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTIFUNGAL AGENTS; APACHE; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 50949116280     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00116-08     Document Type: Article

References (25)

1. Andes, D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. N. Am. 20:679-697.
2. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
3. Andes, D., and M. van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
4. Arikan, S., M. Akova, M. Hayran, O. Ozdemir, M. Erman, D. Gur, and S. Unal. 1998. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin. Infect. Dis. 26:903-908.
5. Baddley, J. W., M. Patel, M. Jones, G. Cloud, A. C. Smith, and S. A. Moser. 2004. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn. Microbiol. Infect. Dis. 50:119-124.
6. Clancy, C. J., B. Staley, and M. H. Nguyen. 2006. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob. Agents Chemother. 50:3496-3498.
7. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snydman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
8. Colombo, A. L., T. Guimaraes, L. R. Silva, L. P. de Almeida Monfardini, A. K. Cunha, P. Rady, T. Alves, and R. C. Rosas. 2007. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect. Control Hosp. Epidemiol. 28:570-576.
9. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
10. Kovacicova, G., Y. Krupova, M. Lovaszova, A. Roidova, J. Trupl, A. Liskova, J. Hanzen, P. Milosevic, M. Lamosova, L. Macekova, Z. Szovenyiova, A. Purgelova, T. Obertik, J. Bille, and V. Krcmery. 2000. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in vitro resistance to fluconazole and the outcome of fungemia? J. Infect. Chemother. 6:216-221.
11. Lee, S. C., C. P. Fung, J. S. Huang, C. J. Tsai, K. S. Chen, H. Y. Chen, N. Lee, L. C. See, and W. B. Shieh. 2000. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother. 44:2715-2718.
12. Louie, A., G. L. Drusano, P. Banerjee, Q. F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
13. Louie, A., Q. F. Liu, G. L. Drusano, W. Liu, M. Mayers, E. Anaissie, and M. H. Miller. 1998. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob. Agents Chemother. 42:1512-1514.
14. Nakamura, T., and H. Takahashi. 2006. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J. Infect. Chemother. 12:132-138.
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
16. Pai, M. P., R. S. Turpin, and K. W. Garey. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 51:35-39.
17. Pappas, P. G. 2006. Invasive candidiasis. Infect. Dis. Clin. N. Am. 20:485-506.
18. Patel, M., D. F. Kunz, V. M. Trivedi, M. G. Jones, S. A. Moser, and J. W. Baddley. 2005. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn. Microbiol. Infect. Dis. 52:29-34.
19. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
20. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
21. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
22. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
23. Rex, J. H., T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, J. E. Edwards, et al. 2000. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30:662-678.
24. Rodriguez-Tudela, J. L., B. Almirante, D. Rodriguez-Pardo, F. Laguna, J. P. Donnelly, J. W. Mouton, A. Pahissa, and M. Cuenca-Estrella. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.
25. Takakura, S., N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, and S. Ichiyama. 2004. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur. J. Clin. Microbiol. Infect. Dis. 23:380-388.